New amphiphilic neamine derivatives active against resistant Pseudomonas aeruginosa and their interactions with lipopolysaccharides

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 8, 2014, Pages 4420-4430

  Sautrey, Guillaume ^a   Zimmermann, Louis ^b   Deleu, Magali ^c   Delbar, Alicia ^a   Machado, Luiza Souza ^b   Jeannot, Katy ^d   Van Bambeke, Françoise ^a   Buyck, Julien M ^a   Decout, Jean Luc ^b   Mingeot Leclercq, Marie Paule ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b UNIV GRENOBLE ALPES   (France)

^c UNIVERSITY OF LIÈGE   (Belgium)

^d UNIVERSITY HOSPITAL OF BESANÇON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; ANTIINFECTIVE AGENT; COLISTIN; FRAMYCETIN; LIPOPOLYSACCHARIDE; NAPHTHALENE DERIVATIVE; NEAMINE;

BINDING SITE; CELL MEMBRANE; CELL MEMBRANE PERMEABILITY; CHEMICAL PHENOMENA; CHEMISTRY; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; HUMAN; MICROBIAL SENSITIVITY TEST; MULTIDRUG RESISTANCE; PSEUDOMONAS AERUGINOSA; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; BINDING SITES; CELL MEMBRANE; CELL MEMBRANE PERMEABILITY; COLISTIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FRAMYCETIN; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; LIPOPOLYSACCHARIDES; MICROBIAL SENSITIVITY TESTS; NAPHTHALENES; PSEUDOMONAS AERUGINOSA; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84905393043     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02536-13     Document Type: Article

References (63)

1. Van Duijn PJ, Dautzenberg MJ, Oostdijk EA. 2011. Recent trends in antibiotic resistance in European ICUs. Curr. Opin. Crit. Care 17:658-665. http://dx.doi.org/10.1097/MCC.0b013e32834c9d87.
2. Herzog T, Chromik AM, Uhl W. 2010. Treatment of complicated intraabdominal infections in the era of multi-drug resistant bacteria. Eur. J. Med. Res. 15:525-532. http://dx.doi.org/10.1186/2047-783X-15-12-525.
3. Rodriguez-Rojas A, Oliver A, Blazquez J. 2012. Intrinsic and environmental mutagenesis drive diversification and persistence of Pseudomonas aeruginosa in chronic lung infections. J. Infect. Dis. 205:121-127. http://dx.doi.org/10.1093/infdis/jir690.
4. Ranall MV, Butler MS, Blaskovich MA, Cooper MA. 2012. Resolving biofilm infections: current therapy and drug discovery strategies. Curr. Drug Targets 13:1375-1385. http://dx.doi.org/10.2174/138945012803530251.
5. Obritsch MD, Fish DN, MacLaren R, Jung R. 2005. Nosocomial infections due to multidrug-resistant Pseudomonas aeruginosa: epidemiology and treatment options. Pharmacotherapy 25:1353-1364. http://dx.doi.org/10.1592/phco.2005.25. 10.1353.
6. Vaara M. 2013. Novel derivatives of polymyxins. J. Antimicrob. Chemother. 68:1213-1219. http://dx.doi.org/10.1093/jac/dkt039.
7. Bergen PJ, Landersdorfer CB, Lee HJ, Li J, Nation RL. 2012. 'Old' antibiotics for emerging multidrug-resistant bacteria. Curr. Opin. Infect. Dis. 25:626-633. http://dx.doi.org/10.1097/QCO.0b013e328358afe5.
8. Biswas S, Brunel JM, Dubus JC, Reynaud-Gaubert M, Rolain JM. 2012. Colistin: an update on the antibiotic of the 21st century. Expert Rev. Anti Infect. Ther. 10:917-934. http://dx.doi.org/10.1586/eri.12.78.
9. Velkov T, Roberts KD, Nation RL, Thompson PE, Li J. 2013. Pharmacologyofpolymyxins: new insights into an 'old' class of antibiotics. Future Microbiol. 8:711-724. http://dx.doi.org/10.2217/fmb.13.39.
10. Epand RF, Pollard JE, Wright JO, Savage PB, Epand RM. 2010. Depolarization, bacterial membrane composition, and the antimicrobial action of ceragenins. Antimicrob. Agents Chemother. 54:3708-3713. http://dx.doi.org/10. 1128/AAC.00380-10.
11. Epand RM, Epand RF, Savage PB. 2008. Ceragenins (cationic steroid compounds), a novel class of antimicrobial agents. Drug News Perspect. 21:307-311. http://dx.doi.org/10.1358/dnp. 2008.21.6.1246829.
12. Joanne P, Falord M, Chesneau O, Lacombe C, Castano S, Desbat B, Auvynet C, Nicolas P, Msadek T, El Amri C. 2009. Comparative study of two plasticins: specificity, interfacial behavior, and bactericidal activity. Biochemistry 48:9372-9383. http://dx.doi.org/10.1021/bi901222p.
13. Thwaite JE, Humphrey S, Fox MA, Savage VL, Laws TR, Ulaeto DO, Titball RW, Atkins HS. 2009. The cationic peptide magainin II is antimicrobial for Burkholderia cepacia-complex strains. J. Med. Microbiol. 58:923-929. http://dx.doi.org/10.1099/jmm.0.008128-0.
14. Fox MA, Thwaite JE, Ulaeto DO, Atkins TP, Atkins HS. 2012. Design and characterization of novel hybrid antimicrobial peptides based on cecropin A, LL-37 and magainin II. Peptides 33:197-205. http://dx.doi.org/10.1016/j. peptides.2012.01.013.
15. Porcelli F, Buck-Koehntop BA, Thennarasu S, Ramamoorthy A, Veglia G. 2006. Structures of the dimeric and monomeric variants of magainin antimicrobial peptides (MSI-78 and MSI-594) in micelles and bilayers, determined by NMR spectroscopy. Biochemistry 45:5793-5799. http://dx.doi.org/10.1021/bi0601813.
16. Mihajlovic M, Lazaridis T. 2010. Antimicrobial peptides in toroidal and cylindrical pores. Biochim. Biophys. Acta 1798:1485-1493. http://dx.doi.org/10. 1016/j.bbamem.2010.04.004.
17. Lazaridis T, He Y, Prieto L. 2013. Membrane interactions and pore formation by the antimicrobial peptide protegrin. Biophys. J. 104:633-642. http://dx.doi.org/10.1016/j.bpj.2012.12.038.
18. Bradshaw J. 2003. Cationic antimicrobial peptides: issues for potential clinical use. BioDrugs 17:233-240. http://dx.doi.org/10.2165/00063030-200317040- 00002.
19. Bera S, Zhanel GG, Schweizer F. 2008. Design, synthesis, and antibacterial activities of neomycin-lipid conjugates: polycationic lipids with potent gram-positive activity. J. Med. Chem. 51:6160-6164. http://dx.doi.org/10. 1021/jm800345u.
20. Bera S, Zhanel GG, Schweizer F. 2010. Antibacterial activities of aminoglycoside antibiotics-derived cationic amphiphiles. Polyol-modified neomycin B-, kanamycin A-, amikacin-, and neamine-based amphiphiles with potent broad spectrum antibacterial activity. J. Med. Chem. 53:3626-3631. http://dx.doi.org/10.1021/jm1000437.
21. Bera S, Zhanel GG, Schweizer F. 2010. Antibacterial activity of guanidinylated neomycin B- and kanamycin A-derived amphiphilic lipid conjugates. J. Antimicrob. Chemother. 65:1224-1227. http://dx.doi.org/10.1093/jac/dkq083.
22. Bera S, Dhondikubeer R, Findlay B, Zhanel GG, Schweizer F. 2012. Synthesis and antibacterial activities of amphiphilic neomycin B-based bilipid conjugates and fluorinated neomycin B-based lipids. Molecules 17:9129-9141. http://dx.doi.org/10.3390/molecules17089129.
23. Herzog IM, Green KD, Berkov-Zrihen Y, Feldman M, Vidavski RR, Eldar-Boock A, Satchi-Fainaro R, Eldar A, Garneau-Tsodikova S, Fridman M. 2012. 6"-Thioether tobramycin analogues: towards selective targeting of bacterial membranes. Angew. Chem. Int. Ed. Engl. 51:5652-5656. http://dx.doi.org/10.1002/ anie.201200761.
24. Zhang J, Keller K, Takemoto JY, Bensaci M, Litke A, Czyryca PG, Chang CW. 2009. Synthesis and combinational antibacterial study of 5"-modified neomycin. J. Antibiot. (Tokyo) 62:539-544. http://dx.doi.org/10.1038/ja.2009.66.
25. Fourmy D, Recht MI, Puglisi JD. 1998. Binding of neomycin-class aminoglycoside antibiotics to the A-site of 16 S rRNA. J. Mol. Biol. 277:347-362. http://dx.doi.org/10.1006/jmbi.1997.1552.
26. Francois B, Russell RJ, Murray JB, Aboul-ela F, Masquida B, Vicens Q, Westhof E. 2005. Crystal structures of complexes between aminoglycosides and decoding A site oligonucleotides: role of the number of rings and positive charges in the specific binding leading to miscoding. Nucleic Acids Res. 33:5677-5690. http://dx.doi.org/10.1093/nar/gki862.
27. Baussanne I, Bussiere A, Halder S, Ganem-Elbaz C, Ouberai M, Riou M, Paris JM, Ennifar E, Mingeot-Leclercq MP, Decout JL. 2010. Synthesis and antimicrobial evaluation of amphiphilic neamine derivatives. J. Med. Chem. 53:119-127. http://dx.doi.org/10.1021/jm900615h.
28. Ouberai M, El Garch F, Bussiere A, Riou M, Alsteens D, Lins L, Baussanne I, Dufrene YF, Brasseur R, Decout JL, Mingeot-Leclercq MP. 2011. The Pseudomonas aeruginosa membranes: a target for a new amphiphilic aminoglycoside derivative? Biochim. Biophys. Acta 1808:1716-1727. http://dx.doi.org/10.1016/j.bbamem.2011. 01.014.
29. Zimmermann L, Bussiere A, Ouberai M, Baussanne I, Jolivalt C, Mingeot-Leclercq MP, Decout JL. 2013. Tuning the antibacterial activity of amphiphilic neamine derivatives and comparison to paromamine homologues. J. Med. Chem. 56:7691-7705. http://dx.doi.org/10.1021/jm401148j.
30. Jackowski O, Bussière A, Vanhaverbeke C, Baussanne I, Peyrin E, Mingeot-Leclercq MP, Décout JL. 2012. Major increases of the reactivity and selectivity in aminoglycoside O-alkylation due to the presence of fluoride ions. Tetrahedron 68:737-746. http://dx.doi.org/10.1016/j.tet.2011.10.102.
31. Clinical and Laboratory Standards Institute. 2013. Performance standards for antimicrobial susceptibility testing: 23rd informational supplement. Document M100-S23. Clinical and Laboratory Standards Institute, Wayne, PA.
32. Stepanovic S, Vukovic D, Dakic I, Savic B, Svabic-Vlahovic M. 2000. A modified microtiter-plate test for quantification of staphylococcal biofilm formation. J. Microbiol. Methods 40:175-179. http://dx.doi.org/10.1016/S0167- 7012 (00) 00122-6.
33. Peeters E, Nelis HJ, Coenye T. 2008. Comparison of multiple methods for quantification of microbial biofilms grown in microtiter plates. J. Microbiol. Methods 72:157-165. http://dx.doi.org/10.1016/j.mimet.2007.11.010.
34. Wood SJ, Miller KA, David SA. 2004. Anti-endotoxin agents. 1. Development of a fluorescent probe displacement method optimized for the rapid identification of lipopolysaccharide-binding agents. Comb. Chem. High Throughput Screen. 7:239-249. http://dx.doi.org/10.2174/1386207043328832.
35. Wood SJ, Miller KA, David SA. 2004. Anti-endotoxin agents. 2. Pilot high-throughput screening for novel lipopolysaccharide-recognizing motifs in small molecules. Comb. Chem. High Throughput Screen. 7:733-747. http://dx.doi.org/10.2174/1386207043328229.
36. Hunter CA, Anderson HL. 2009. What is cooperativity? Angew. Chem. Int. Ed. Engl. 48:7488-7499. http://dx.doi.org/10.1002/anie.200902490.
37. Provencher SW. 1982. A constrained regularization method for inverting data represented by linear algebraic or integral equations. Comput. Phys. Commun. 27:229-242. http://dx.doi.org/10.1016/0010-4655 (82) 90174-6.
38. Parasassi T, De Stasio G, Ravagnan G, Rusch RM, Gratton E. 1991. Quantitation of lipid phases in phospholipid vesicles by the generalized polarization of laurdan fluorescence. Biophys. J. 60:179-189. http://dx.doi.org/10.1016/S0006-3495 (91) 82041-0.
39. Parasassi T, Gratton E. 1995. Membrane lipid domains and dynamics as detected by laurdan fluorescence. J. Fluoresc. 5:59-69. http://dx.doi.org/10. 1007/BF00718783.
40. Loh B, Grant C, Hancock RE. 1984. Use of the fluorescent probe 1-N-phenylnaphthylamine to study the interactions of aminoglycoside antibiotics with the outer membrane of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 26:546-551. http://dx.doi.org/10.1128/AAC.26.4.546.
41. Wu M, Hancock RE. 1999. Interaction of the cyclic antimicrobial cationic peptide bactenecin with the outer and cytoplasmic membrane. J. Biol. Chem. 274:29-35. http://dx.doi.org/10.1074/jbc.274.1.29.
42. Helander IM, Mattila-Sandholm T. 2000. Fluorometric assessment of gram-negative bacterial permeabilization. J. Appl. Microbiol. 88:213-219. http://dx.doi.org/10.1046/j.1365-2672.2000.00971.x.
43. Hancock RE, Wong PG. 1984. Compounds which increase the permeability of the Pseudomonas aeruginosa outer membrane. Antimicrob. Agents Chemother. 26:48-52. http://dx.doi.org/10.1128/AAC.26.1.48.
44. Buyck JM, Tulkens PM, Van Bambeke F. 2013. Pharmacodynamic evaluation of the intracellular activity of antibiotics towards Pseudomonas aeruginosa PAO1 in a model of THP-1 human monocytes. Antimicrob. Agents Chemother. 57:2310-2318. http://dx.doi.org/10.1128/AAC.02609-12.
45. Moskowitz SM, Brannon MK, Dasgupta N, Pier M, Sgambati N, Miller AK, Selgrade SE, Miller SI, Denton M, Conway SP, Johansen HK, Hoiby N. 2012. PmrB mutations promote polymyxin resistance of Pseudomonas aeruginosa isolated from colistin-treated cystic fibrosis patients. Antimicrob. Agents Chemother. 56:1019-1030. http://dx.doi.org/10.1128/AAC.05829-11.
46. Miller AK, Brannon MK, Stevens L, Johansen HK, Selgrade SE, Miller SI, Hoiby N, Moskowitz SM. 2011. PhoQ mutations promote lipid A modification and polymyxin resistance of Pseudomonas aeruginosa found in colistin-treated cystic fibrosis patients. Antimicrob. Agents Chemother. 55:5761-5769. http://dx.doi.org/10.1128/AAC.05391-11.
47. Gutu AD, Sgambati N, Strasbourger P, Brannon MK, Jacobs MA, Haugen E, Kaul RK, Johansen HK, Hoiby N, Moskowitz SM. 2013. Polymyxin resistance of Pseudomonas aeruginosa phoQ mutants is dependent on additional two-component regulatory systems. Antimicrob. Agents Chemother. 57:2204-2215. http://dx.doi.org/10.1128/AAC.02353-12.
48. Papp-Wallace KM, Endimiani A, Taracila MA, Bonomo RA. 2011. Carbapenems: past, present, and future. Antimicrob. Agents Chemother. 55:4943-4960. http://dx.doi.org/10.1128/AAC.00296-11.
49. Vaara M, Vaara T. 1981. Outer membrane permeability barrier disruption by polymyxin in polymyxin-susceptible and -resistant Salmonella typhimurium. Antimicrob. Agents Chemother. 19:578-583. http://dx.doi.org/10.1128/AAC.19.4. 578.
50. Hancock RE, Bell A. 1988. Antibiotic uptake into gram-negative bacteria. Eur. J. Clin. Microbiol. Infect. Dis. 7:713-720. http://dx.doi.org/10.1007/ BF01975036.
51. Velkov T, Thompson PE, Nation RL, Li J. 2010. Structure-activity relationships of polymyxin antibiotics. J. Med. Chem. 53:1898-1916. http://dx.doi.org/10.1021/jm900999h.
52. Pristovsek P, Kidric J. 1999. Solution structure of polymyxins B and E and effect of binding to lipopolysaccharide: an NMR and molecular modeling study. J. Med. Chem. 42:4604-4613. http://dx.doi.org/10.1021/jm991031b.
53. Hancock RE, Chapple DS. 1999. Peptide antibiotics. Antimicrob. Agents Chemother. 43:1317-1323.
54. Santos NC, Silva AC, Castanho MA, Martins-Silva J, Saldanha C. 2003. Evaluation of lipopolysaccharide aggregation by light scattering spectroscopy. Chembiochem 4:96-100. http://dx.doi.org/10.1002/cbic.200390020.
55. Giuliani A, Pirri G, Rinaldi AC. 2010. Antimicrobial peptides: the LPS connection. Methods Mol. Biol. 618:137-154. http://dx.doi.org/10.1007/978-1- 60761-594-1-10.
56. Domadia PN, Bhunia A, Ramamoorthy A, Bhattacharjya S. 2010. Structure, interactions, and antibacterial activities of MSI-594 derived mutant peptide MSI-594F5A in lipopolysaccharide micelles: role of the helical hairpin conformation in outer-membrane permeabilization. J. Am. Chem. Soc. 132:18417-18428. http://dx.doi.org/10.1021/ja1083255.
57. Bhunia A, Domadia PN, Torres J, Hallock KJ, Ramamoorthy A, Bhattacharjya S. 2010. NMR structure of pardaxin, a pore-forming antimicrobial peptide, in lipopolysaccharide micelles: mechanism of outer membrane permeabilization. J. Biol. Chem. 285:3883-3895. http://dx.doi.org/10.1074/jbc. M109.065672.
58. Lins RD, Straatsma TP. 2001. Computer simulation of the rough lipopolysaccharide membrane of Pseudomonas aeruginosa. Biophys. J. 81:1037-1046. http://dx.doi.org/10.1016/S0006-3495 (01) 75761-X.
59. Ravi HK, Stach M, Soares TA, Darbre T, Reymond JL, Cascella M. 2013. Electrostatics and flexibility drive membrane recognition and early penetration by the antimicrobial peptide dendrimer bH1. Chem. Commun. (Camb.) 49:8821-8823. http://dx.doi.org/10.1039/c3cc44912b.
60. Murata T, Tseng W, Guina T, Miller SI, Nikaido H. 2007. PhoPQ-mediated regulation produces a more robust permeability barrier in the outer membrane of Salmonella enterica serovar Typhimurium. J. Bacteriol. 189:7213-7222. http://dx.doi.org/10.1128/JB.00973-07.
61. Soon RL, Li J, Boyce JD, Harper M, Adler B, Larson I, Nation RL. 2012. Cell surface hydrophobicity of colistin-susceptible vs resistant Acinetobacter baumannii determined by contact angles: methodological considerations and implications. J. Appl. Microbiol. 113:940-951. http://dx.doi.org/10.1111/j.1365- 2672.2012.05337.x.
62. Pelletier MR, Casella LG, Jones JW, Adams MD, Zurawski DV, Hazlett KR, Doi Y, Ernst RK. 2013. Unique structural modifications are present in the lipopolysaccharide from colistin-resistant strains of Acinetobacter baumannii. Antimicrob. Agents Chemother. 57:4831-4840. http://dx.doi.org/10.1128/AAC.00865- 13.
63. Prokhorenko IR, Zubova SV, Ivanov AY, Grachev SV. 2009. Interaction of Gram-negative bacteria with cationic proteins: dependence on the surface characteristics of the bacterial cell. Int. J. Gen. Med. 2:33-38.